Triple Inhaled Therapy at Two Glucocorticoid Doses in Moderate-to-Very-Severe COPD

RCT (n=8509) found triple therapy with twice-daily budesonide (at 160 or 320μg dose), glycopyrrolate, and formoterol resulted in lower annual rate of moderate/severe COPD exacerbations than glycopyrrolate–formoterol or budesonide–formoterol (1.07, 1.08, 1.42 & 1.24, respectively)

SPS commentary:

The triple-combination therapy (budesonide/glycopyrronium/formoterol fumarate) is to be marketed under brand name, Breztri Aerosphere, and is currently under regulatory review in the US and EU for treatment of COPD.


New England Journal of Medicine